Ustekinumab as Induction and Maintenance Therapy in Patients with Inflammatory Bowel Disease and Type II Autoimmune Pancreatitis: Report of Two Cases

J Crohns Colitis. 2023 Oct 20;17(9):1552-1554. doi: 10.1093/ecco-jcc/jjad072.
No abstract available

Publication types

  • Case Reports

MeSH terms

  • Autoimmune Pancreatitis* / chemically induced
  • Crohn Disease*
  • Humans
  • Inflammatory Bowel Diseases* / chemically induced
  • Remission Induction
  • Treatment Outcome
  • Ustekinumab / therapeutic use

Substances

  • Ustekinumab